<DOC>
	<DOCNO>NCT02055560</DOCNO>
	<brief_summary>The primary objective study evaluate whether management colorectal cancer ( CRC ) patient 5-fluorouracil ( 5-FU ) exposure optimization test reduces 5-FU related toxicity improve outcome compare current standard care . A secondary objective characterize variability 5-FU level among CRC patient manage 5-FU exposure optimization test impact management 5-FU plasma level drug dose course chemotherapy .</brief_summary>
	<brief_title>Retrospective Evaluation 5-FU Exposure Optimization CRC Patients</brief_title>
	<detailed_description>This multi-center retrospective match cohort study early late stage CRC patient receive 5-FU dos determine use body surface area ( BSA ) patient underwent pharmacokinetically ( PK ) -guided 5-FU dose monitoring adjustment . A retrospective chart / electronic medical record review colorectal cancer patient treat infusional 5-FU regimen May 1 , 2009 December 31 , 2013 , satisfy inclusion/exclusion criterion , perform . In multi-center study , patient underwent PK-testing least two different 5-FU administration match patient receive dos base BSA , treat institution . Matching selection BSA cohort site do use follow criterion ( base factor may influence 5-FU metabolism ) : age , gender , disease stage , prior chemotherapy treatment , 5-FU contain treatment regimen use . Each patient assign random five-digit Study ID number protect patient confidentiality . Minimal medical history/demographics data collect patient 's medical record / clinic chart use paper case report form ( CRFs ) . The data collect patient 's record include : patient demographic ( i.e . gender , age , height , race ) , colorectal cancer diagnosis ( i.e . date primary diagnosis , tumor stage , grade , histology phenotype , date metastatic diagnosis sit metastasis applicable ) , use prior therapy treatment CRC , 5-FU contain regimen detail throughout 5-FU treatment ( i.e . weight , BSA , ECOG status , dose drug use regimen , 5-FU infusion start/stop date time ) , 5-FU PK test result ( applicable ) , concomitant procedure medication , CBC chemistry test result , adverse event experience 5-FU therapy regimen , tumor response follow-up information . Patients contact purpose study waiver HIPAA authorization request appropriate IRB . Once data collect monitored , record tie random Study ID number specific patient site destroy , render information de-identified .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Male female patient 18 year age old . Patients histologically confirm colorectal cancer treat infusional 5FU regimen May 1 , 2009 December 31 , 2013 . PKGuided Cohort : Patients monitor 5FU PKtesting minimum two administration 5FU throughout course single infusional 5FU contain treatment regimen . BSA Cohort : Patients receive infusional 5FU dos calculate base BSA . Patients le 18 year age . Patients concurrent treatment active malignancy . Patients underwent radiation therapy concurrently chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>colorectal</keyword>
	<keyword>OnDose</keyword>
	<keyword>MyCare</keyword>
	<keyword>5-FU</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>exposure</keyword>
	<keyword>optimization</keyword>
	<keyword>dose adjustment</keyword>
</DOC>